DE69130831T2 - Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen - Google Patents

Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen

Info

Publication number
DE69130831T2
DE69130831T2 DE69130831T DE69130831T DE69130831T2 DE 69130831 T2 DE69130831 T2 DE 69130831T2 DE 69130831 T DE69130831 T DE 69130831T DE 69130831 T DE69130831 T DE 69130831T DE 69130831 T2 DE69130831 T2 DE 69130831T2
Authority
DE
Germany
Prior art keywords
mixtures
synthesis
amino acid
disclosed
coupled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69130831T
Other languages
English (en)
Other versions
DE69130831D1 (de
Inventor
Richard Houghten
Julio CUERVO
Clemencia Pinilla
Jon Appel
Silvie Blondelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITEREX PHARMA LP
Original Assignee
ITEREX PHARMA LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITEREX PHARMA LP filed Critical ITEREX PHARMA LP
Application granted granted Critical
Publication of DE69130831D1 publication Critical patent/DE69130831D1/de
Publication of DE69130831T2 publication Critical patent/DE69130831T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00279—Features relating to reactor vessels
    • B01J2219/00281—Individual reactor vessels
    • B01J2219/00295—Individual reactor vessels the reactor vessels having pervious side walls
    • B01J2219/00297—"Tea bags"
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00457—Dispensing or evacuation of the solid phase support
    • B01J2219/00459—Beads
    • B01J2219/00461—Beads and reaction vessel together
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/005—Beads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00585—Parallel processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/0059—Sequential processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00592—Split-and-pool, mix-and-divide processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00596—Solid-phase processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
DE69130831T 1990-11-21 1991-11-20 Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen Expired - Fee Related DE69130831T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61702390A 1990-11-21 1990-11-21
US70165891A 1991-05-16 1991-05-16
US79755191A 1991-11-19 1991-11-19
PCT/US1991/008694 WO1992009300A1 (en) 1990-11-21 1991-11-20 Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures

Publications (2)

Publication Number Publication Date
DE69130831D1 DE69130831D1 (de) 1999-03-11
DE69130831T2 true DE69130831T2 (de) 1999-09-16

Family

ID=27417190

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130831T Expired - Fee Related DE69130831T2 (de) 1990-11-21 1991-11-20 Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen

Country Status (11)

Country Link
US (2) US5556762A (de)
EP (1) EP0558671B1 (de)
JP (1) JP3523252B2 (de)
AT (1) ATE176239T1 (de)
AU (1) AU668347B2 (de)
CA (1) CA2090860C (de)
DE (1) DE69130831T2 (de)
DK (1) DK0558671T3 (de)
ES (1) ES2129442T3 (de)
GR (1) GR3030061T3 (de)
WO (1) WO1992009300A1 (de)

Families Citing this family (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
US6197529B1 (en) 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
IL102168A (en) * 1991-06-18 1998-12-06 Lilly Co Eli Rapid synthesis and filtration of peptide mimetics
US5672472A (en) * 1991-08-23 1997-09-30 Isis Pharmaceuticals, Inc. Synthetic unrandomization of oligomer fragments
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
US5885965A (en) * 1991-11-01 1999-03-23 Periodontix, Inc. Anti-fungal D-amino acid histatin-based peptides
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
CA2137378C (en) * 1992-06-05 2008-08-05 Stephen Brian Henry Kent D-enzyme compositions and methods of their use
US5721099A (en) * 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5565324A (en) * 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US6503759B1 (en) 1992-10-01 2003-01-07 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5807683A (en) * 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
AU6281594A (en) * 1993-03-12 1994-09-26 Jerini Bio Chemicals Gmbh Process for synthesizing and selecting sequences of covalently bound components
US5786327A (en) 1993-03-12 1998-07-28 Gensci Regeneration Sciences Inc. Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same
US6864048B2 (en) 1993-04-28 2005-03-08 Affymetrix, Inc. Factorial chemical libraries
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
JPH09500625A (ja) 1993-07-09 1997-01-21 スミスクライン・ビーチャム・コーポレイション 環状セミランダムペプチドライブラリー
AU7193494A (en) * 1993-07-21 1995-02-20 Oxford Glycosystems Ltd Saccharides, their synthesis and use
CN1525171A (zh) * 1993-10-01 2004-09-01 ŦԼ�и��ױ��Ǵ�ѧ���� 用标示物编码的多元组合化学库
CA2175579A1 (en) * 1993-10-26 1995-05-04 Chang Yi Wang Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US5503805A (en) * 1993-11-02 1996-04-02 Affymax Technologies N.V. Apparatus and method for parallel coupling reactions
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
JPH09510688A (ja) * 1993-12-15 1997-10-28 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｃｘｃインタークリン分子のペプチド阻害剤
US5965536A (en) * 1993-12-15 1999-10-12 Board Of Regents, The University Of Texas System Methods of inhibiting CXC intercrine molecules
JPH09506611A (ja) * 1993-12-15 1997-06-30 コンビケム，インコーポレイテッド 組合わせライブラリーおよびその使用法
US5587471A (en) * 1994-01-11 1996-12-24 Isis Pharmaceuticals, Inc. Method of making oligonucleotide libraries
EP0739486A4 (de) * 1994-01-13 1998-09-09 Univ Columbia Synthetische rezeptoren, bibliotheken und ihre verwendung
US6936477B2 (en) 1994-04-13 2005-08-30 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5738996A (en) * 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5824483A (en) * 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5939268A (en) * 1994-07-26 1999-08-17 The Scripps Research Institute Combinatorial libraries of molecules and methods for producing same
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US6020312A (en) * 1994-09-13 2000-02-01 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US5885782A (en) * 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US5602097A (en) * 1994-09-13 1997-02-11 Ceres Technologies, Inc. Synthetic antibiotics
US20020169104A1 (en) * 1997-05-01 2002-11-14 Glenn Frank Novel ectoparasite saliva proteins and apparatus to collect such proteins
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US5741462A (en) 1995-04-25 1998-04-21 Irori Remotely programmable matrices with memories
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US5925562A (en) * 1995-04-25 1999-07-20 Irori Remotely programmable matrices with memories
US6025129A (en) * 1995-04-25 2000-02-15 Irori Remotely programmable matrices with memories and uses thereof
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
US6352973B1 (en) * 1995-06-07 2002-03-05 Osteopharm Inc. Bone stimulating factor
US6693081B2 (en) * 1995-09-26 2004-02-17 Osteopharm Inc. Bone stimulating factor
US5763263A (en) * 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
US20020142352A1 (en) * 1999-03-04 2002-10-03 Heska Corporation Novel ectoparasite salvia proteins and apparatus to collect such proteins
US6110889A (en) 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
US6280967B1 (en) 1996-08-02 2001-08-28 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time of cellular responses
US6558916B2 (en) * 1996-08-02 2003-05-06 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time measurements of patient cellular responses
US5804436A (en) * 1996-08-02 1998-09-08 Axiom Biotechnologies, Inc. Apparatus and method for real-time measurement of cellular response
AUPO161196A0 (en) * 1996-08-13 1996-09-05 Commonwealth Scientific And Industrial Research Organisation Novel compounds
EP0935608A4 (de) * 1996-09-27 2004-09-15 Biomolecular Res Inst Ltd Cytotoxische peptide
ATE347101T1 (de) * 1996-10-07 2006-12-15 Discovery Partners Internation System zur synthese einer verbindungsbibliotek und dessen verwendung
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
US6617114B1 (en) 1996-10-31 2003-09-09 Karo Bio Ab Identification of drug complementary combinatorial libraries
US6441172B1 (en) 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
US5859191A (en) * 1996-12-05 1999-01-12 The Regents Of The University Of California Method for the site-specific modification of peptide alpha amines
EP0990142A4 (de) 1996-12-31 2000-09-27 Genometrix Genomics Inc Molekulares multiplexanalyse verfahren und vorrichtung dazu
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
US5908960A (en) * 1997-05-07 1999-06-01 Smithkline Beecham Corporation Compounds
US6004823A (en) * 1997-05-07 1999-12-21 Smithkline Beecham Corporation Compounds
WO1998050438A1 (en) * 1997-05-08 1998-11-12 Smithkline Beecham Corporation Chloride linker for solid phase organic synthesis
CA2305597C (en) 1997-11-07 2008-07-29 Conjuchem Inc. Affinity markers for human serum albumin
US6190920B1 (en) 1997-11-12 2001-02-20 The Regents Of The University Of California Method for detecting enzyme catalyzed cyclization
US20100105572A1 (en) * 1997-12-19 2010-04-29 Kris Richard M High throughput assay system
US20030096232A1 (en) * 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
US20030039967A1 (en) * 1997-12-19 2003-02-27 Kris Richard M. High throughput assay system using mass spectrometry
GB9808783D0 (en) * 1998-04-25 1998-06-24 Central Research Lab Ltd Labelling of small articles
US6872535B2 (en) 1998-05-20 2005-03-29 Aventis Pharmaceuticals Inc. Three-dimensional array of supports for solid-phase parallel synthesis and method of use
US6541211B1 (en) 1998-05-20 2003-04-01 Selectide Corporation Apparatus and method for synthesizing combinational libraries
EP2360271A1 (de) 1998-06-24 2011-08-24 Illumina, Inc. Dekodierung von Arraysensoren mit Mikrosphären
CA2350141C (en) * 1998-11-13 2009-01-06 Pepscan Systems B.V. A method for determining a mimotope sequence
US6846460B1 (en) 1999-01-29 2005-01-25 Illumina, Inc. Apparatus and method for separation of liquid phases of different density and for fluorous phase organic syntheses
AU3482200A (en) 1999-02-02 2000-08-25 Bernhard Palsson Methods for identifying drug targets based on genomic sequence data
US6500609B1 (en) 1999-02-11 2002-12-31 Scynexis Chemistry & Automation, Inc. Method and apparatus for synthesizing characterizing and assaying combinatorial libraries
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
US6524863B1 (en) 1999-08-04 2003-02-25 Scynexis Chemistry & Automation, Inc. High throughput HPLC method for determining Log P values
US6413431B1 (en) 1999-08-10 2002-07-02 Scynexis Chemistry & Automation, Inc. HPLC method for purifying organic compounds
EP1218545B1 (de) 1999-08-18 2012-01-25 Illumina, Inc. Methoden zur erzeugung von oligonukleotidlösungen
US6387273B1 (en) 1999-08-27 2002-05-14 Scynexis Chemistry & Automation, Inc. Sample preparation for high throughput purification
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US6545032B1 (en) 1999-09-17 2003-04-08 Torrey Pines Institute For Molecular Studies Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
US6632616B2 (en) * 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
BR0111718A (pt) * 2000-06-16 2003-09-09 Hercules Inc Peptìdeos quimicamente modificados, composições e métodos de produção e uso
EP1292609A2 (de) * 2000-06-16 2003-03-19 Hercules Incorporated Peptide, zusammesetzungen und verfahren zur behandlung von burkholderia cepacia
CA2412513A1 (en) * 2000-06-22 2001-12-27 San Diego State University Foundation Modulators of recombination and methods for producing and using the same
US6759510B1 (en) * 2000-06-30 2004-07-06 Becton, Dickinson And Company Peptides for use in culture media
EP1326892A2 (de) 2000-10-12 2003-07-16 University of Rochester Zusammensetzungen die die proliferation von krebszellen hemmen
US20040229382A1 (en) * 2000-10-23 2004-11-18 Ronald Breaker Characterized arrangements of mixtures (CAM) using polymers
DE10059890A1 (de) * 2000-12-01 2002-06-20 Hte Ag Verfahren zur Herstellung einer Vielzahl von Bausteinen einer Materialbibliothek
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
US7127379B2 (en) * 2001-01-31 2006-10-24 The Regents Of The University Of California Method for the evolutionary design of biochemical reaction networks
US20030059792A1 (en) * 2001-03-01 2003-03-27 Palsson Bernhard O. Models and methods for determining systemic properties of regulated reaction networks
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
MXPA03010037A (es) 2001-05-01 2004-06-30 Univ California Moleculas de fusion y metodos para tratamiento de enfermedades inmunes.
WO2002090599A1 (en) 2001-05-09 2002-11-14 Genetic Id, Inc. Universal microarray system
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2002100172A1 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Administration of agents via the pept-2 transporter
EP2000482A1 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
CA2453403C (en) 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
CN1216068C (zh) * 2001-07-13 2005-08-24 一泰医药研究（深圳）有限公司 序列号14的生物活性肽
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7751981B2 (en) 2001-10-26 2010-07-06 The Regents Of The University Of California Articles of manufacture and methods for modeling Saccharomyces cerevisiae metabolism
US20060258581A1 (en) * 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
CN1615148A (zh) * 2001-11-21 2005-05-11 伯纳姆研究院 用于对iap抑制卡斯蛋白酶进行去阻遏的方法及组合物
US20050119176A1 (en) * 2001-11-21 2005-06-02 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003209030B2 (en) 2002-02-06 2009-02-05 Stasys Technologies, Inc. Anti-infarction molecules
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
US20030224363A1 (en) * 2002-03-19 2003-12-04 Park Sung M. Compositions and methods for modeling bacillus subtilis metabolism
CA2480216A1 (en) 2002-03-29 2003-10-09 Genomatica, Inc. Human metabolic models and methods
US8949032B2 (en) 2002-03-29 2015-02-03 Genomatica, Inc. Multicellular metabolic models and methods
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2003089455A2 (en) * 2002-04-22 2003-10-30 Dow Global Technologies Inc. Low-cost production of peptides
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7856317B2 (en) 2002-06-14 2010-12-21 Genomatica, Inc. Systems and methods for constructing genomic-based phenotypic models
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
EP1575515A4 (de) * 2002-08-29 2007-08-08 Genentech Inc Achaete-scute-ähnliche 2 polypeptide und kodierende nukleinsäuren und verfahren zur diagnose und behandlung eines tumors
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
AU2003294220A1 (en) 2002-09-17 2004-04-23 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
US7869957B2 (en) 2002-10-15 2011-01-11 The Regents Of The University Of California Methods and systems to identify operational reaction pathways
WO2004035009A2 (en) 2002-10-15 2004-04-29 The Regents Of The University Of California Methods and systems to identify operational reaction pathways
AU2003295824A1 (en) * 2002-11-22 2004-06-18 Incyte Corporation Cell adhesion and extracellular matrix proteins
WO2004050701A1 (en) * 2002-12-05 2004-06-17 Osteopharm Inc. Bone growth factor
EP1608673A2 (de) * 2003-03-28 2005-12-28 The Rockefeller University Peptide und mimetika zur reduzierung der symptome von toxischem schocksyndrom und septischem schock
AU2004259638C1 (en) 2003-07-08 2018-12-20 Novartis Pharma Ag IL-17 A/F heterologous polypeptides and therapeutic uses thereof
DK2161283T3 (da) 2003-11-17 2014-09-01 Genentech Inc SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE
US20050136538A1 (en) * 2003-12-17 2005-06-23 Srikant Pathak Lithographic method for attaching biological cells to a solid substrate using a small molecule linker
US8900856B2 (en) 2004-04-08 2014-12-02 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20050261474A1 (en) * 2004-05-20 2005-11-24 Mixture Sciences, Inc. Method of support-based chemical synthesis
EP1600455A1 (de) * 2004-05-28 2005-11-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Herstellung Festphasen gebundener Peptide oder PNAs
US7488804B2 (en) 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
AU2006223498A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
CN101500481B (zh) 2005-04-05 2014-07-02 康宁股份有限公司 一种测定刺激事件对细胞产生的影响的方法
AU2005332058B2 (en) 2005-05-19 2011-12-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof
EP2186402A1 (de) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out Tiermodelle für neue Gene und deren Verwendung
CA2619577A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2189522A1 (de) 2005-10-14 2010-05-26 MUSC Foundation For Research Development PAX2 als Ziel zur Induktion einer Immunität gegen DEFB1-vermittelte Tumore und bei der Krebstherapie
US7576037B2 (en) 2005-11-18 2009-08-18 Mei Technologies, Inc. Process and apparatus for combinatorial synthesis
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP3006466B1 (de) 2005-12-02 2018-08-01 Genentech, Inc. Zusammensetzungen und verfahren für die behandlung von krankheiten und störungen in zusammenhang mit der zytokinsignalisierung
JP2009527227A (ja) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2010662A2 (de) 2006-04-19 2009-01-07 Genentech, Inc. Neuartige genunterbrechungen, dazugehörige zusammensetzungen und verfahren
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
EP2057465A4 (de) 2006-08-09 2010-04-21 Homestead Clinical Corp Organspezifische proteine und anwendungsverfahren dafür
ES2372217T3 (es) 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
CA2981308C (en) 2006-09-21 2020-12-22 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
US7834140B2 (en) * 2006-10-12 2010-11-16 Saint Louis University Polypeptide fragment of constitutive coactivator of PPARgamma
EP2104516B1 (de) 2006-11-01 2015-01-07 University of Rochester Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
EP2117575A4 (de) 2007-01-03 2013-06-05 Burnham Inst Medical Research Verfahren und zusammensetzungen in verbindung mit gerinnselbindenden verbindungen
EP2117576B1 (de) 2007-02-08 2014-04-16 University Of Utah Research Foundation Verfahren und zusammensetzungen zur viruseindringungshemmung
PL2140021T3 (pl) 2007-02-22 2012-06-29 Genentech Inc Sposobu wykrywania nieswoistego zapalenia jelit
EP3327142A1 (de) * 2007-07-13 2018-05-30 University of Pittsburgh- Of the Commonwealth System of Higher Education Von virus abstammende antimikrobielle peptide
US20090023182A1 (en) * 2007-07-18 2009-01-22 Schilling Christophe H Complementary metabolizing organisms and methods of making same
WO2009043476A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Neuromedin s as a therapeutic agent
AU2008303896A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008303868A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
NZ584330A (en) * 2007-10-04 2013-01-25 Bionomics Ltd Markers of endothelial cells and uses thereof
PT2514436T (pt) 2007-11-07 2018-03-21 Genentech Inc Il-22 para utilização no tratamento de distúrbios microbianos
WO2009079373A2 (en) 2007-12-14 2009-06-25 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
WO2009105591A2 (en) 2008-02-19 2009-08-27 The Regents Of The University Of California Methods and systems for genome-scale kinetic modeling
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010027641A2 (en) * 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
DK2403935T3 (en) 2009-03-04 2017-09-11 Univ Pennsylvania COMPOSITIONS CONTAINING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP3187877A1 (de) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening-verfahren
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
CN102741294A (zh) 2009-11-30 2012-10-17 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
RU2595389C2 (ru) 2010-02-23 2016-08-27 Дженентек, Инк. Композиции и способы для диагностики и лечения опухолей
JP6092091B2 (ja) * 2010-03-16 2017-03-08 デピュイ・シンセス・プロダクツ・インコーポレイテッド Ｂｍｐ−２に対し親和性をもつペプチド
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2598660B1 (de) 2010-07-26 2017-03-15 Biomatrica, INC. Zusammensetzungen zur stabilisierung von dna, rna und proteinen in blut- und anderen biologischen proben während des transports und der lagerung bei umgebungstemperaturen
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
US8112218B2 (en) * 2011-03-10 2012-02-07 Ford Global Technologies, Llc Method for controlling an engine
GB2503604B (en) 2011-03-21 2020-04-22 Biodesy Llc Classification of kinase inhibitors using second harmonic optical techniques
WO2012135385A1 (en) 2011-03-28 2012-10-04 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
BR112014005720A2 (pt) 2011-09-15 2017-12-12 Genentech Inc método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
AU2012328457A1 (en) 2011-10-28 2014-04-24 Presage Biosciences, Inc. Methods for drug delivery
RU2014133547A (ru) 2012-01-18 2016-03-10 Дженентек, Инк. Способы применения модуляторов fgf19
JP6545959B2 (ja) 2012-02-11 2019-07-17 ジェネンテック， インコーポレイテッド Ｒスポンジン転位およびその使用方法
WO2013137920A1 (en) 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
RU2014141018A (ru) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг Способы лечения меланомы ингибиторами рак1
CN106290917B (zh) 2012-04-25 2020-06-05 比奥德赛公司 用于检测蛋白质的变构调节剂的方法
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP2855528B1 (de) 2012-05-31 2019-06-19 Genentech, Inc. Verfahren zur krebsbehandlung mit pd-l1-achsenbindenden antagonisten und vegf-antagonisten
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
PL2972373T3 (pl) 2013-03-15 2020-03-31 F. Hoffmann-La Roche Ag Biomarkery i sposoby leczenia stanów związanych z PD-1 i PD-L1
SI2970422T1 (en) 2013-03-15 2018-07-31 F. Hoffmann-La Roche Ag IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
PT3021869T (pt) 2013-07-16 2020-09-10 Hoffmann La Roche Métodos de tratamento do cancro com antagonistas da ligação ao eixo pd-1 e inibidores do tigit
BR112016013741A2 (pt) 2013-12-17 2017-10-03 Genentech Inc Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US8961992B1 (en) 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
EP3146071B1 (de) 2014-05-23 2020-09-02 F. Hoffmann-La Roche AG Mit-biomarker und verfahren mit verwendung davon
EP3154338B1 (de) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilisierung von thrombozyten bei umgebungstemperatur
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP3169361B1 (de) 2014-07-15 2019-06-19 F.Hoffmann-La Roche Ag Zusammensetzungen zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und mek-inhibitoren
EP3188746A4 (de) 2014-09-05 2018-05-02 The Johns Hopkins University Capn9/capns2-aktivität als ziel für eine therapeutische strategie zur behandlung von myofibroblastendifferenzierung und assoziierten erkrankungen
EP4141032A1 (de) 2014-11-20 2023-03-01 F. Hoffmann-La Roche AG Kombinationstherapie von t-zell-aktivierenden bispezifischen antigenbindenden molekülen und pd-1-achsen-bindenden antagonisten
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
US10376535B2 (en) 2015-03-26 2019-08-13 University Of Rochester Therapy for malignant disease
US10881733B2 (en) 2015-05-22 2021-01-05 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
US20180188257A1 (en) 2015-06-19 2018-07-05 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
US20180282415A1 (en) 2015-09-30 2018-10-04 Merck Patent Gmbh Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
EP3371211A4 (de) 2015-11-04 2019-08-21 Icahn School of Medicine at Mount Sinai Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
EP4242628A3 (de) 2015-12-08 2023-11-08 Biomatrica, INC. Verringerung der erythrozytensedimentationsrate
US10898483B2 (en) 2015-12-23 2021-01-26 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
WO2017139329A1 (en) 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity lables
US11246868B2 (en) 2016-04-26 2022-02-15 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
MX2019003425A (es) 2016-09-28 2019-08-16 Blade Therapeutics Inc Moduladores de calpainas y usos terapeuticos de los mismos.
US10780080B2 (en) 2016-11-23 2020-09-22 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
JP7169979B2 (ja) 2017-02-27 2022-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体関連腎症および肝線維症の候補治療剤の治療有効性を評価する方法
CN106916205B (zh) * 2017-03-31 2020-10-13 重庆理工大学 抗菌六肽及其衍生物和应用
TW201841656A (zh) 2017-04-21 2018-12-01 美商建南德克公司 Ｋｌｋ５拮抗劑用於治療疾病之用途
EP3615569A1 (de) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
WO2018237326A1 (en) 2017-06-22 2018-12-27 1AlMOONSHOT PHARMA LLC METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNOMODULATORS
EP3655430A1 (de) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose und behandlung von hepatitis-b-virusinfektionen
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
JP2021502418A (ja) 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
TW201929907A (zh) 2017-12-22 2019-08-01 美商建南德克公司 Pilra結合劑用於治療疾病之用途
CN110102263A (zh) * 2019-04-10 2019-08-09 中国药科大学 巯基乙胺功能化磁性氧化石墨烯吸附剂及其制备方法和应用
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN114616240A (zh) 2019-11-08 2022-06-10 高等教育联邦***-匹兹堡大学 包含抗微生物肽的组合物
JP2023545566A (ja) 2020-10-20 2023-10-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１軸結合アンタゴニストとｌｒｒｋ２阻害剤との併用療法
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
EP4351582A1 (de) 2021-06-09 2024-04-17 F. Hoffmann-La Roche AG Kombination eines bestimmten braf-hemmers (paradoxbrecher) und eines pd-1-achsenbindenden antagonisten zur verwendung bei der behandlung von krebs
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3544404A (en) * 1968-01-05 1970-12-01 Burlington Industries Inc Method of making polypropylene bags
US4304692A (en) * 1978-07-24 1981-12-08 Armour Pharmaceutical Company Synthesis of biologically active peptides
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4282143A (en) * 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
EP0138854B1 (de) * 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigen aktive aminosäuresequenzen
US4483964A (en) * 1983-06-20 1984-11-20 Chiron Corporation Reactor system and method for polynucleotide synthesis
US4507433A (en) * 1983-10-07 1985-03-26 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
CA1255586A (en) * 1984-07-24 1989-06-13 Hendrik M. Geysen Method of determining mimotopes
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US4831211A (en) * 1988-06-08 1989-05-16 Rockwell International Corporation EMI/RFI sealed microphonics isolation apparatus and methods
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures

Also Published As

Publication number Publication date
CA2090860A1 (en) 1992-05-22
DK0558671T3 (da) 1999-09-13
EP0558671B1 (de) 1999-01-27
JPH06507378A (ja) 1994-08-25
EP0558671A1 (de) 1993-09-08
JP3523252B2 (ja) 2004-04-26
GR3030061T3 (en) 1999-07-30
US5556762A (en) 1996-09-17
ES2129442T3 (es) 1999-06-16
US5504190A (en) 1996-04-02
ATE176239T1 (de) 1999-02-15
AU668347B2 (en) 1996-05-02
WO1992009300A1 (en) 1992-06-11
EP0558671A4 (en) 1994-05-11
DE69130831D1 (de) 1999-03-11
CA2090860C (en) 2003-09-16
AU9141891A (en) 1992-06-25

Similar Documents

Publication Publication Date Title
DE69130831T2 (de) Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
RU93056644A (ru) Способ получения ароматических соединений
ATE215559T1 (de) Peralkylierte oligopeptidmischungen
DK0400583T3 (da) Imidazoquinoxalinoner,deres azaanaloger og fremgangsmåde til fremstilling deraf
DE69022604T2 (de) Verfahren zum Herstellen von Unterwasserbauwerken.
DK15589A (da) Kemiske forbindelser
DE68905379T2 (de) Verfahren zur Reinigung von Stickstofftrifluoridgas.
DE69015504T2 (de) Stickstoffgasherstellungsverfahren.
MY107819A (en) Preparation of substituted piperidines.
DK0402322T3 (da) Fremgangsmåde til fremstilling af R(+)-aminocarnitin og S(-)-aminocarnitin
BE841860A (fr) Procede d'etancheification utilisant des matieres a base de produits d'addition d'isocyanates
DE69010956T2 (de) Verfahren zur Synthese von Acylaminogruppen enthaltenden Siliziumverbindungen.
DK63689A (da) Fremgangsmaade til modificering af en molekylesigte
DE69006888D1 (de) Verfahren zur Synthese von Acylamino-Organosilicon-Verbindungen.
DK0527079T3 (da) N-(isoquinolin-5-yl)-sulfonyl-azacykloalkaner, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
EP0249039A3 (en) Process for granulating azobisamidine salt
CA2032303A1 (en) Inhibitors of retroviral proteases
DK653589A (da) Fremgangsmaade til fremstilling af reaktionsproduktblanding omfattende di-substituerede-imidazolinforbindelser og toejbloedgoeringsmiddel omfattende samme
DK126288D0 (da) Fremgangsmaade til fremstilling af polychlorphosphazen
DK0635491T3 (da) (Thia)cycloalkylab indoler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse forbindelser.
NO962542D0 (no) Forbedret fremgangsmåte for syntese av 2-amino-3,5-dihydro-7-substituerte 4H-pyrrolo (3,2-d) pyrimidin-4-oner
DE69002500T2 (de) Verfahren zur Synthese von N-Methyl-3,4-dimethoxyphenylethylamin.
DK580586D0 (da) Partikelformet detergentenzymprodukt og fremgangsmaade til fremstilling deraf
RU93035505A (ru) Способ синтеза 1,2,5-триметилпиперидин-4-она из доступных видов российского сырья
RU94030731A (ru) Асимметрично замещенные производные диаминодикарбоновой кислоты и способ их получения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee